close
NEW: LANDSCAPE IN GENE THERAPY COMPANIES 2019
News

NEW: LANDSCAPE IN GENE THERAPY COMPANIES 2019

LANDSCAPE IN GENE THERAPY COMPANIES 2019

        BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their up-dated and enriched 2019 edition of their report entitled “Landscape… in Gene Therapy Companies”.  This report provides you with an in-depth analysis of more than 230 companies involved in this expanding field.
(UPDATED SEP 2019)

In this 800-pages report, a must-have read one, you will find included:

 • More than 230 closely scrutinized companies
• More than 600 products identified
including more than 200 products at the clinical stage
 • More than 300 VC or investors mentioned
  • More than 250 pathologies referred.

 A Detailed Overview of Companies Involved in

 • AAV-based Gene Therapy
LV-based Gene Therapy
RNA-based Derived Drugs (RNAi, mRNA Therapeutics…)
 • Gene Editing Therapy
 • CDMO (Contract, Development and Manufacturing Organisation)
Miscellaneous (Including Hubs and Non Viral Gene Transfer)

CAR-T strategies will be dealt separately in the updated edition of our briefing on CAR-T clinical trials. The 2019 edition will be published next November.

Each Technical Datasheet includes for Every Company

General Informations (location, website, FTE, management with e-mail contacts)
Core Business in Gene Therapy
Financial Data (stock informations, market cap, financial highlights, recent fundings….)
Pipeline (discovery, pre-clinical, phase I / II / III, marketed products)
Orphan Drug Designations
Clinical Trials
Latest Developments in Gene Therapy
Latest Publications

ORDER BEFORE OCTOBER 15th AND SAVE 15 %

Click to get  sample pages of Landscape in Gene Therapy Companies 2019

Click to get the Order Form or go to Studies to get the Report


COMMENTS ARE OFF THIS POST